ESTRO meets Asia 2024 - Abstract Book

S37

Invited Speaker

ESTRO meets Asia 2024

delayed treatment is only 10 in two years. The superconducting accelerator is becoming usual machine for medical use.

For the future advance, particle therapy technologies has more rooms for improvement to catch up with those in advanced photon therapy: arc therapy, MRI-guided therapy, and adaptive therapy. These development will be desirable, however, the advantage of high LET, will be critically important for the treatment of radioresistant tumor. To further improve this advantage, LET optimization using proton or carbon, and multiple ion therapy irradiation has been started. For further compact facility, superconducting synchrotron for carbon ion therapy is under development. These advances will be expected to improve clinical outcome and increase of the number of facility.

526

Proton and carbon therapy: technical advantages and pitfall from the physics point of view

Hyeongmin Jin

Radiation Oncology, Seoul National University Hospital, Seoul, Korea, Republic of. Project Group of the Gijang Heavy Ion Medical Accelerator, Seoul National University Hospital, Seoul, Korea, Republic of

Abstract

Particle therapy offers significant advancements in radiation oncology due to its precise energy deposition and minimizing damage to surrounding tissues. This talk examines the technical advantages and pitfalls from a physicist perspective, offering insights into ongoing challenges and emerging solutions in the field. Range uncertainty presents a major challenge in particle therapy, primarily due to variations in tissue density and composition, which affect the stopping power. Techniques such as dual energy computed tomography for improved stopping power prediction and robust optimization strategies for planning are explored to mitigate these effects. Motion management is critical for maintaining accuracy in dose delivery in the presence of patient and tumor motion. This talk discusses the interplay effect, the use of immobilization devices, and advanced adaptive techniques like rescanning and gating systems that synchronize radiation delivery with target movement. Furthermore, the current state of biological modeling in particle therapy is evaluated, highlighting existing models and their limitations

527

Clinical benefit of Hadron therapy (p+ and C+)

Tatsuya Ohno

Department of Radiation Oncology, Gunma University, Aramaki-machi, Japan

Abstract

In Japan, there are 25 particle therapy facilities in operation (6 carbon-ion radiotherapy facilities, 19 proton therapy facilities, and one provides both carbon-ion and proton therapy). Particle therapy has long been practiced under a program of Advanced Medical Care. Particle therapy in the program has been evaluated every two years by the Ministry of Health, Labour and Welfare and assigned to one of the following categories: 1) move to Public Health